Delivery Order SPE2DB22D3301-SPE2DB25FZ0AW
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,519.62 for 120 tablets of Lynparza 100 mg on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside transaction executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be performed...
- The Defense Logistics Agency awarded a $42,078.48 firm fixed price delivery order to AmerisourceBergen Drug Corp for 120 tablets of Lynparza 100 mg, with an ultimate completion date of August 29, 2025. This is a non-set-aside competitive award issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,543.70 for 60 tablets of Lynparza 100 mg on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and is being fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Lynparza 150 mg tablets (120 count units) with a ceiling value of $42,270.40. This is a firm fixed-price delivery order with no set-aside designation, executed under competitive procurement procedures. The order is scheduled for ultimate completion by September 15, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. As a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of LYNPARZA 100 mg tablets (120-count units) with a ceiling value of $10,519.62. This firm fixed-price delivery order, with an ultimate completion date of September 9, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. LYNPARZA is an oncology pharmaceutical used in cancer treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $10,519.62 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Lynparza 100 mg tablets (120-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 30, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- This delivery order, awarded May 1, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides 120 tablets of Lynparza 150 mg under a firm fixed price contract valued at $10,567.60, with completion scheduled for May 22, 2025. The award carries no set-aside designation and represents a competitively awarded delivery order for a brand-name oncology medication. This order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Lynparza 150 mg tablets (120-count units) with a firm fixed price ceiling value of $21,135.20 and ultimate completion date of September 10, 2025. This delivery order represents a non-competitive award and is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Lynparza 150 mg tablets (120 count) valued at $31,702.80. This firm fixed-price delivery order is scheduled for completion by August 25, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Lynparza 150 mg tablets (120 count) with a contract value of $10,567.60. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 2, 2025. This delivery order...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0AWDelivery Order
This delivery order, awarded August 26, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides 120 tablets of Lynparza 100 mg at a ceiling value of $10,519.62. The award is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with a completion date of September 17, 2025. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. Lynparza (olaparib) is an oncology medication used in cancer treatment, representing part of AmerisourceBergen's comprehensive pharmaceutical supply portfolio to federal healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen serves critical medical procurement needs for military and veteran healthcare systems through the DLA Medical Supply Chain. The delivery order exemplifies the company's role as a primary vendor supplying specialty medications and branded pharmaceuticals across multiple therapeutic domains to support Defense Health Agency and other federal healthcare operations. AmerisourceBergen's competitive position in federal medical procurement is demonstrated through its extensive contract awards with DLA involving firm fixed pricing and delivery orders spanning various pharmaceutical product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 8/26/25 |